Wednesday, 12 Dec 2018

You are here

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Using prospective clinic data and clinical assessments in a cohort of PsA patients, 171 patients (52% male, mean age 46.6 years) were studied. More than half (56%) reported chronic back pain.  Inflammatory back was either rheumatologist defined or defined by one of 3 accepted criteria for IBP (Calin, Rudwaleit, ASAS).

Inflammatory back pain was seen in 38% of patients and 32% had evidence of radiological changes in the spine.

The agreement between rheumatologist judgement of IBP and criteria used for IBP was highest for the Calin criteria (0.70).

Rudwaleit criteria for IBP (2.17) had the highest positive likelihood ratio for radiological axial involvement.

Amongst AxPsA with or without back pain, those with back pain had higher BASDAI scores and lower frequency of HLA-B*38 .

IBP as judged by the rheumatologist does not always agree with IBP criteria, nor will all have xrays changes of spondylitis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.